What is the official website of Novartis Malaysia ?

The official website of Novartis Malaysia is https://www.novartis.com.my/.

What is Novartis Malaysia's cybersecurity risk score?

Novartis Malaysia has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Malaysia experienced?

According to Rankiteo, Novartis Malaysia currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Malaysia been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Malaysia has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Malaysia have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Malaysia is not certified under SOC 2 Type 1.

Does Novartis Malaysia have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Malaysia does not hold a SOC 2 Type 2 certification.

Does Novartis Malaysia comply with GDPR ?

According to Rankiteo, Novartis Malaysia is not listed as GDPR compliant.

Does Novartis Malaysia have PCI DSS certification ?

According to Rankiteo, Novartis Malaysia does not currently maintain PCI DSS compliance.

Does Novartis Malaysia comply with HIPAA ?

According to Rankiteo, Novartis Malaysia is not compliant with HIPAA regulations.

Does Novartis Malaysia have ISO 27001 certification ?

According to Rankiteo,Novartis Malaysia is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Malaysia operate in ?

Novartis Malaysia operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Malaysia have ?

Novartis Malaysia employs approximately 135 people worldwide.

Does Novartis Malaysia own any subsidiaries ?

Novartis Malaysia presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Malaysia have ?

Novartis Malaysia's official LinkedIn profile has approximately 7,159 followers.

What is the NAICS classification code for Novartis Malaysia ?

Novartis Malaysia is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Malaysia have a Crunchbase profile ?

No, Novartis Malaysia does not have a profile on Crunchbase.

Does Novartis Malaysia have a LinkedIn profile ?

Yes, Novartis Malaysia maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartismalaysia.

How many cybersecurity incidents has Novartis Malaysia experienced ?

As of August 30, 2026, Rankiteo reports that Novartis Malaysia has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Malaysia have ?

Novartis Malaysia has an estimated 5,746 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Malaysia faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Malaysia

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Novartis Malaysia Vendor Cyber Rating & Cyber Score

novartis.com.my

Add Your Compliance Badge

We strive to change the practice of medicine. To make discoveries that take medicine in new directions. Privacy Policy: https://www.novartis.com/my-en/privacy-policy Novartis LinkedIn Community Guidelines: https://www.novartis.com/guidelines/novartis-linkedin-community-guidelines

Novartis Malaysia A.I CyberSecurity Scoring

Scoring History

Novartis Malaysia

Novartis Malaysia CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Malaysia

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Malaysia Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Malaysia

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Malaysia in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Malaysia in 2026.

Incident Types Novartis Malaysia vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Malaysia in 2026.

Incident History - Novartis Malaysia (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Malaysia Subsidiaries

Novartis Malaysia

Pharmaceutical Manufacturing

Website: https://www.novartis.com.my/

Company Size: 501-1,000 employees

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis EuropePharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Loading…

Novartis Malaysia Similar Companies

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Loading…

NEWS

Novartis Malaysia CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-82424

SUMMARY

A weakness has been identified in PHPGurukul Student Information System 1.0. Affected by this vulnerability is an unknown functionality of the file /student_edit1.php. Executing a manipulation of the argument ID can lead to sql injection. The attack can be launched remotely. The exploit has been made available to the public and could be used for attacks.

Published

Date2026-08-29

Updated

Date2026-08-29

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-82423

SUMMARY

A vulnerability has been found in macrozheng mall up to 1.0.3. The affected element is an unknown function of the file /order/paySuccess of the component Payment Status Endpoint. The manipulation of the argument orderId leads to enforcement of behavioral workflow. The attack is possible to be carried out remotely. The vendor deleted the GitHub issue for this vulnerability without any explanation.

Published

Date2026-08-29

Updated

Date2026-08-29

RISK INFORMATION (Score: 5.4)

cvss2

Base Score: 5.5

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:P/A:P

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

2.5

Exploitability

2.8

REFERENCES

CVE-2026-82422

SUMMARY

A security flaw has been discovered in itsourcecode Sales and Inventory System 1.0. Impacted is an unknown function of the file /pages/emp_del.php. The manipulation of the argument ID results in sql injection. The attack may be launched remotely. The exploit has been released to the public and may be used for attacks.

Published

Date2026-08-29

Updated

Date2026-08-29

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-82421

SUMMARY

A vulnerability was identified in itsourcecode Sales and Inventory System 1.0. This issue affects some unknown processing of the file /pages/emp_edit.php. The manipulation of the argument ID leads to sql injection. The attack may be initiated remotely. The exploit is publicly available and might be used.

Published

Date2026-08-29

Updated

Date2026-08-29

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-15369

SUMMARY

The Custom User Registration Fields for WooCommerce plugin for WordPress is vulnerable to Privilege Escalation in versions up to, and including, 2.2.3. This is due to the plugin accepting an attacker-controlled afreg_select_user_role value from the unauthenticated WooCommerce Store API /wc/store/v1/checkout request in the af_reg_checkout_data_to_order_meta_data_block() function, persisting it in order meta, and then passing it directly to WP_User::add_role() in the af_reg_custom_order_processing_function() function (hooked to woocommerce_thankyou) without validating against the plugin's admin-configured allowed role list. This makes it possible for unauthenticated attackers to elevate their privileges to Administrator by creating an account during checkout with a modified JSON body specifying administrator (or any other role slug) as the desired role. Note: The exploit requires the "User Role Selection" setting to be enabled.

Published

Date2026-08-29

Updated

Date2026-08-29

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…